InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,440.00
(
2.13%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
-1.03%
)
Bitcoin
62,618.27
(
5.92%
)
Post# of 29293
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119562
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 28370

Thursday, 07/20/2023 12:25:49 PM

Thursday, July 20, 2023 12:25:49 PM

Post# of 29293
ABT 2Q23 Results by Business Segment 
  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency) 
 Medical devices*  43%       +14% 
 Diagnostics       23%       -46%† 
 Nutrition         21%       +10% 
 Branded generics  13%       +13%
62% of overall corporate sales were ex-US.

*Includes diabetes care.

†2Q23 COVID-diagnostics sales were $263M (11% of total 2Q23 diagnostic sales) vs $2.3B in 2Q22; excluding COVID diagnostics, 2Q23 diagnostics sales were +7% YoY.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up